FDA Approves New Targeted Oral Therapy for Metastatic Pancreatic Cancer

The FDA has approved daraxonrasib, a first-in-class targeted oral therapy for adults with metastatic pancreatic adenocarcinoma. This new drug, evaluated in the global Phase 3 RASolute 302 trial, significantly extended patient survival compared to standard chemotherapy, marking a major advancement for this aggressive cancer.